6th International RASopathies Symposium: Precision Medicine - from Promise to Practice
第六届国际 RASopathies 研讨会:精准医学 - 从承诺到实践
基本信息
- 批准号:9763367
- 负责人:
- 金额:$ 3.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvocateAffectBiologyCancer BiologyCardiovascular systemCaringCell physiologyClinicalClinical TrialsClinical assessmentsCommunicationCommunitiesCostello syndromeCutaneousDevelopmentDiagnosticDiagnostic ServicesDiseaseDoctor of PhilosophyDysmorphologyEtiologyExtracellular Signal Regulated KinasesFaceFamilyFamily memberFutureGene MutationGenesGeneticGenetic Predisposition to DiseaseGerm-Line MutationGleanGoalsHumanIndividualInternationalKnowledgeLearningLegius syndrome LogisticsMalignant NeoplasmsMarylandMedicalMitogen-Activated Protein KinasesMolecularMolecular GeneticsMultiple LentiginesMusculoskeletalMutationNeurocognitive DeficitNeurodevelopmental DisorderNeurofibromatosis 1Noonan SyndromeOralPainParentsParticipantPathogenicityPathway interactionsPatientsPediatric HospitalsPerinatalPhenotypePopulationPredispositionPrevalencePublic HealthQuality of lifeRas InhibitorReadinessResearchResearch PersonnelResourcesScientistSeriesSeveritiesSignal TransductionStandardizationSyndromeTherapeuticUpdatebody systemcardiofaciocutaneous syndromeclinical diagnosticsclinical phenotypedevelopmental diseaseexperiencefallsgastrointestinalgenetic counselorinterestknowledge basemeetingsmemberpostersprecision medicinepreclinical studyprogramssymposium
项目摘要
PROJECT SUMMARY
Germline mutations in genes affecting Ras/extracellular signal regulated kinase (ERK) signaling result in
syndromic disorders collectively termed “RASopathies”. In aggregate, the prevalence of RASopathy disorders,
including neurofibromatosis type 1 (NF1), Noonan syndrome (NS), NS with multiple lentigines (NSML), Legius
syndrome, Costello syndrome (CS), and cardio-facio-cutaneous syndrome (CFC), among others, is at least
~1/1000, comprising one of the largest groups of neurodevelopmental disorders. Given a common etiology in
dysregulated Ras/ERK signaling, these syndromes display overlapping phenotypic manifestations affecting
most, if not all, major organ systems and include neurocognitive impairment; cardiovascular, musculoskeletal,
cutaneous, and gastrointestinal problems; predisposition to cancer, and pain. The RASopathies have a
profound impact on quality of life for affected individuals and families, and require mobilization of considerable
resources for ongoing medical care.
The 6th International RASopathies Symposium: Precision Medicine – From Promise to Practice, to be held
August 2-4, 2019 at the Marriott Delta Hotel, Hunt Valley, MD, will convene clinicians, researchers, biopharma
scientists, trainees, family groups, and individuals affected by a RASopathy. The goals are to share and
discuss new scientific and clinical findings, grow the community knowledge base, encourage new investigators
to focus on issues facing RASopathy patients, and devise patient-informed strategies for future preclinical
studies and clinical trials leveraging the substantial progress being made in the development of inhibitors for
Ras/ERK-driven cancers. The program agenda will consist of a poster session, scientific oral presentations,
panel discussions, networking opportunities, and shared meals. In this way, the symposium provides unique
opportunities for scientists, clinicians, and affected families to interact outside of the typical clinical setting.
Participants and attendees will collaborate in describing the burden of Ras-related disorders, their
management, and planning for therapeutic advances in the near future.
The meeting chairs are Karen W. Gripp, MD, Director of the RASopathies Research Program at Nemours
duPont Hospital for Children, and Nancy Ratner, PhD, Co-Director of the RASopathy Program at Cincinnati
Children's Hospital. Leaders of the RASopathies Network organization, Lisa Schoyer, MFA (PI), Lisa Schill, BS
(Co-I), and Beth Stronach, PhD (Co-I) are parent advocates and will help organize and manage meeting
logistics. The symposium will overlap with the Costello Syndrome Family Network conference and provide
programming relevant to families with other RASopathies.
项目摘要
影响Ras/细胞外信号调节激酶(ERK)信号传导的基因中的种系突变导致
综合征性疾病统称为“RASopathies”。总的来说,RAS病的患病率,
包括1型神经纤维瘤病(NF 1)、努南综合征(NS)、NS伴多发性雀斑样痣(NSML)、军团菌病(Legius
综合征、Costello综合征(CS)和心-面-皮肤综合征(CFC)等,至少
约1/1000,是神经发育障碍的最大群体之一。由于共同的病因,
Ras/ERK信号转导失调,这些综合征表现出重叠的表型表现,
大多数(如果不是全部的话)主要器官系统,包括神经认知障碍;心血管,肌肉骨骼,
皮肤和胃肠道问题;易患癌症和疼痛。RASopathies有一个
对受影响个人和家庭的生活质量产生深远影响,需要动员相当多的
持续医疗护理的资源。
第六届国际RASopathies研讨会:精准医疗-从承诺到实践,将举行
2019年8月2日至4日,在马里兰州亨特谷的万豪三角洲酒店,将召集临床医生,研究人员,生物制药
科学家、受训人员、家庭团体和受RAS病影响的个人。我们的目标是分享和
讨论新的科学和临床发现,发展社区知识基础,鼓励新的研究人员
关注RAS病患者面临的问题,并为未来的临床前研究制定患者知情的策略,
研究和临床试验利用了在开发抑制剂方面取得的实质性进展,
Ras/ERK驱动的癌症。该计划的议程将包括一个海报会议,科学口头报告,
小组讨论、交流机会和共享膳食。通过这种方式,研讨会提供了独特的
科学家、临床医生和受影响家庭在典型临床环境之外进行互动的机会。
参与者和与会者将合作描述Ras相关疾病的负担、他们的
管理,并计划在不久的将来的治疗进展。
会议主席是Karen W。Gripp,医学博士,Nemours的RASopathies研究项目主任
杜邦儿童医院和Nancy Ratner博士,辛辛那提RASopathy项目的联合主任
儿童医院RASopathies网络组织的领导人,丽莎Schoyer,MFA(PI),丽莎Schill,BS
(Co-I)和Beth Stronach博士(Co-I)是家长倡导者,将帮助组织和管理会议
物流研讨会将与科斯特洛综合征家庭网络会议重叠,并提供
与患有其他RASopathies的家庭相关的节目。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lisa Schoyer其他文献
Lisa Schoyer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lisa Schoyer', 18)}}的其他基金
8th International RASopathies Symposium: Expanding Research and Care Practice through Global Collaboration and Advocacy
第八届国际 RASopathies 研讨会:通过全球合作和宣传扩大研究和护理实践
- 批准号:
10683644 - 财政年份:2023
- 资助金额:
$ 3.3万 - 项目类别:
2021 International RASopathies Symposium
2021年国际RASopathies研讨会
- 批准号:
10237583 - 财政年份:2021
- 资助金额:
$ 3.3万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 3.3万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 3.3万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 3.3万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 3.3万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 3.3万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 3.3万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 3.3万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 3.3万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 3.3万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 3.3万 - 项目类别: